China's First PMTA Non-Clinical Lab by Feelm Analysis Center

Jul.29.2022
China's First PMTA Non-Clinical Lab by Feelm Analysis Center
China's first non-clinical PMTA testing laboratory has been built by the Analytical Testing and Safety Assessment Center (ATSA).

Recently, it has been reported that the Analytical Testing and Safety Assessment Center (referred to as the "Safety Assessment Center") of Smoler has established China's first PMTA (pre-market tobacco application) comprehensive non-clinical testing laboratory. The laboratory currently covers PMTA non-clinical research requirements, including material safety, harmful and potentially harmful constituents (HPHCs) and toxicity testing.


This is the first PMTA testing laboratory established domestically, which will assist the global leading provider of closed-system electronic cigarette solutions, Smoore, and its flagship brand FEELM, in further improving product safety and helping partner brands successfully pass PMTA certification.


The only laboratory in China that covers all substances in HPHCs.


Before this, electronic cigarette companies that wanted to enter the international market had to rely on third-party partners to complete PMTA testing, which was expensive and time-consuming. With the establishment of a new domestic laboratory, FEELM's brand partners can more easily undergo PMTA certification, increasing their chances of entering the international market.


Dr. Long, the director of the Smyrna Evaluation Center, has revealed that the FDA has placed significant emphasis on HPHCs and has identified a list of 33 substances to be tested. The Smyrna Evaluation Center is currently capable of testing 37 substances and is the only laboratory in the country that has the ability to test all substances included in the list of HPHCs.


The laboratory conducted tests using the world-leading HPHCs (harmful and potentially harmful constituents) database developed by Philip Morris International, which is based on multiple authoritative international toxicity databases. In addition, the lab incorporated advanced computational toxicology software to predict unidentified and potential harmful constituents not included in the database, further enhancing Philip Morris's safety assessment capabilities.


Assist brand clients in entering the overseas market.


Since the establishment of its first basic research institute in 2017, Simoer has been continuously expanding its global leading detection projects and building a comprehensive product safety verification system. Currently, Simoer's safety evaluation center has established the industry's first E&L (extractables and leachables) analysis testing laboratory, raising the material safety standard for electronic atomization to medical grade, and recently completed a toxicity testing laboratory that is now open to FEELM customers.


Smol intends to become the driving force behind electronic cigarette brands approaching the FDA and other regulatory agencies, allowing the brand to enter a broader overseas market. To date, eight of their products have been approved by the FDA for market release, with several produced by Smol, indicating FDA recognition of the processes and testing mechanisms in their new laboratory in China. Concurrently, Smol is collaborating with brand partners and FEELM customers to expand their testing scope and provide stronger support for product design, while also preparing to release safety reports.


This article contains excerpts or reprints from third-party sources, and their copyright belongs to the original media and authors. If there is any infringement, please contact us for deletion. Any organization or individual who wants to reprint must contact the author and should not directly reprint.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

IQOS Japan Introduces Multiple Pastel-Style UV-Printed Designs for ILUMA i, Available Until April 20
IQOS Japan Introduces Multiple Pastel-Style UV-Printed Designs for ILUMA i, Available Until April 20
The official IQOS Japan Instagram account posted that IQOS ILUMA i has introduced multiple exterior designs featuring pastel-style UV prints (a UV-curing printing process), adding spring colors to the regular device lineup, with limited-time sales at IQOS Stores through April 20.
Apr.10 by 2FIRSTS.ai
New York’s Lawsuit Against Puff Bar and Other Flavored Vape Companies Survives Key Court Challenge
New York’s Lawsuit Against Puff Bar and Other Flavored Vape Companies Survives Key Court Challenge
According to Law360, a federal judge ruled that makers and distributors of flavored vape brands such as Puff Bar cannot escape New York’s lawsuit seeking to hold them responsible for the youth vaping epidemic. The court found that the state had adequately alleged the companies misrepresented how safe vaping is.
Apr.07 by 2FIRSTS.ai
From myblu to Zone: Imperial Brands Refocuses NGP Strategy in HY26
From myblu to Zone: Imperial Brands Refocuses NGP Strategy in HY26
mperial Brands’ HY26 results point to a more selective NGP transition. The company is using cash flow from traditional tobacco to fund targeted investments in modern oral nicotine, heated tobacco and reusable vaping systems. Its decision to exit the legacy myblu vaping business in the U.S., while expanding Zone nicotine pouches. In Europe, Imperial’s NGP growth is being driven by a multi-category portfolio including blu, Pulze and Zone/Skruf.
Special Report
May.12
FDA Launches Elsa 4.0 and Completes HALO Data Platform Consolidation
FDA Launches Elsa 4.0 and Completes HALO Data Platform Consolidation
The U.S. Food and Drug Administration announced on May 6 that it has advanced its modernization initiative by launching Elsa 4.0, an upgraded internal AI tool, and consolidating more than 40 application and submission data sources, systems and portals into a new platform called HALO. FDA said the integration of HALO and Elsa will allow staff to query data and build workflows without manually uploading documents in each chat.
May.07 by 2FIRSTS.ai
Philip Morris International Announces IQOS and Devialet Collaboration at Milan Design Week 2026
Philip Morris International Announces IQOS and Devialet Collaboration at Milan Design Week 2026
Philip Morris International announced on April 20 that IQOS has partnered with French acoustic engineering company Devialet to launch “Soundsorial Design” at Milan Design Week 2026. The collaboration includes an immersive exhibition and a limited-edition product set named “Soundsorial.” The exhibition will run from April 20 to April 27 at Opificio 31 in Milan.
Apr.22 by 2FIRSTS.ai
New York Nicotine Pouch Tax Moves Forward as Critics Question Public Health Impact
New York Nicotine Pouch Tax Moves Forward as Critics Question Public Health Impact
New York Governor Kathy Hochul included in her FY 2027 budget proposal a plan to impose the same 75% wholesale tax on nicotine pouches such as Zyn that applies to cigarettes. The measure is expected to raise USD 18 million in FY 2027 and USD 44 million in FY 2028 after full implementation.
Mar.30 by 2FIRSTS.ai